Plasma levels of chemokines during leprosy specific treatment

Acta Tropica

Volumn 113, Issue 2, 2010, Pages 151-154

  Mendonça, Vanessa Amaral ^a   Costa, Rosane Dias ^b   Lyon, Sandra ^b   Penido, Rachel Adriana ^c   Borges, Valdinéria Oliveira ^a   Bretas, Thales Lage ^a   Antunes, Carlos Mauricio ^a   Teixeira, Mauro Martins ^a   Teixeira, Antonio Lúcio ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FUNDAÇÃO HOSPITALAR DO ESTADO DE MINAS GERAIS   (Brazil)

^c Instituto Superior Anísio Teixeira Fundação Helena Antipoff   (Brazil)

Author keywords

CCL11 eotaxin 1; CCL24 eotaxin 2; Chemokines; Leprosy; Treatment

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE; CLOFAZIMINE; DAPSONE; EOTAXIN; EOTAXIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RIFAMPICIN;

BIOMARKER; CONCENTRATION (COMPOSITION); DISEASE TREATMENT; LEPROSY; MEASUREMENT METHOD; OBSERVATIONAL METHOD; PLASMA; PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LEPROSY; MALE; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

ADULT; AGED; CHEMOKINE CCL11; CHEMOKINE CCL24; CHEMOKINES; CLOFAZIMINE; DAPSONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LABORATORIES; LEPROSTATIC AGENTS; LEPROSY; MALE; MIDDLE AGED; MYCOBACTERIUM LEPRAE; RIFAMPIN; TREATMENT OUTCOME;

MYCOBACTERIUM LEPRAE;

EID: 74149085250     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actatropica.2009.10.010     Document Type: Article

References (21)

1. Alessandri A.L., Souza A.L., Oliveira S.C., Macedo G.C., Teixeira M.M., and Teixeira A.L. Concentrations of CXCL8, CXCL9 and sTNFr1 in plasma of patients with pulmonary tuberculosis undergoing treatment. Inflamm. Res. 55 (2006) 528-533
2. Bandeira-Melo C., Herbst A., and Weller P.F. Eotaxins: contributing to the diversity of eosinophil recruitment and activation. Am. J. Respir. Cell Mol. Biol. 24 (2001) 653-657
3. Belgaumkar V.A., Gokhale N.R., Mahajan P.M., Bharadwaj R., Pandit D.P., and Deshpande S. Circulating cytokine profiles in leprosy patients. Lepr. Rev. 78 (2007) 223-230
4. Charo I.F., and Ransohoff R.M. The roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354 (2006) 610-621
5. Faber W.R., Iyer A.M., Fajardo T.T., Dekker T., Villahermosa L.G., Abalos R.M., and Das P.K. Serial measurement of serum cytokines, cytokine receptors and neopterin in leprosy patients with reversal reactions. Lepr. Rev. 75 (2004) 274-281
6. Gutierrez-Ramos J.C., Lloyd C., and Gonzalo J.A. Eotaxin: from an eosinophilic chemokine to a major regulator of allergic reactions. Immunol. Today 20 (1999) 500-504
7. Hasan Z., Mahmood A., Zafar S., Khan A., and Hussian R. Leprosy patients with lepromatous disease have an up-regulated IL-8 response that is unlinked to TNFα responses. Int. J. Lepr. Other Mycobact. Dis. 72 (2004) 35-44
8. Iyer A., Hatta M., Usman R., Luiten S., Oskam L., Faber W., Geluk A., and Das P. Serum levels of interferon-γ, tumour necrosis factor-α, soluble interleukin-6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions. Clin. Exp. Immunol. 150 (2007) 210-216
9. Jin T., Xu X., and Hereld D. Chemotaxis, chemokine receptors and human disease. Cytokine 44 (2008) 1-8
10. Kirkaldy A.A., Musonda A.C., Khanolkhar-Young S., Suneetha S., and Lockwood D.N.J. Expression of CC and CXC chemokines and chemokine receptors in human leprosy skin lesions. Clin. Exp. Immunol. 134 (2003) 447-453
11. Lew W., Chang S., Tada Y., Nakmura K., and Tamaki K. Serum monocyte chemoattractant protein-1 is elevated in lepromatous leprosy patients with high bacterial indices. Int. J. Lepr. Other Mycobact. Dis. 70 (2002) 129-131
12. Méndez-Samperio P. Expression and regulation of chemokines in mycobacterial infection. J. Infect. 57 5 (2008) 374-384
13. Mendonça V.A., Malaquias L.C., Brito-Melo G.E.A., Castelo-Branco A., Antunes C.M., Ribeiro A.L., Teixeira M.M., and Teixeira A.L. Differentiation of patients with leprosy from non-infected individuals by the chemokine eotaxin/CCL11. Am. J. Trop. Med. Hyg. 77 (2007) 547-550
14. Mendonça V.A., Costa R.D., Brito-Melo G.E.A., Antunes C.M., and Teixeira A.L. Imunologia da hanseníase. Ann. Bras. Dermatol. 83 4 (2008) 343-350 (article in Portuguese)
15. Scollard D.M., Adams L.B., Gillis T.P., Krahenbuhl J.L., Truman R.W., and Williams D.L. The continuing challenges of leprosy. Clin. Microbiol. Rev. 19 (2006) 338-381
16. Silva E.A., Iyer A., Ura S., Lauris J.R., Naafs B., Das P.K., and Vilani-Moreno F. Utility of measuring serum levels of anti-PGL-I antibody, neopterin and C-reactive protein in monitoring leprosy patients during multi-drug treatment and reactions. Trop. Med. Int. Health 12 (2007) 1450-1458
17. Sousa L., Botoni F.A., Britto R.R., Rocha M.O.C., Teixeira Jr. A.L., Teixeira M.M., Reis A.M., Oliveira B.M., and Ribeiro A.L. Six-minute walk test in chagas cardiomyopathy. Int. J. Cardiol. 125 (2008) 139-141
18. Stefani M.M., Guerra J.G., Sousa A.L.M., Costa M.B., Oliveira M.L.W., Martelli C.T., and Scollard D.M. Potential plasma markers of type 1 and type 2 leprosy reactions: a preliminary report. BMC Infect. Dis. 9 (2009) 75
19. World Health Organization. Chemotherapy of leprosy for control programmes. World Health Organ. Tech. Rep. Ser. 675 (1982) 1-33
20. World Health Organization (WHO). Guide to Eliminate Leprosy as a Public Health Problem. 1st ed. (1995), World Health Organization, Geneva
21. World Health Organization. Global leprosy situation, 2008. Weekly Epidemiol. Record. 83 (2008) 293-300